Hosted on MSN4d
Talazoparib-Enzalutamide Improves Survival in Metastatic CRPC
Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...
Medscape4d
Talazoparib Combo Prolongs Survival in Metastatic Prostate Cancer
Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...
Targeted Oncology5d
Talazoparib Plus Enzalutamide Extends Survival in mCRPC
Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...
Cancer Therapy Advisor6d
Talazoparib Improves OS as First-Line Treatment in mCRPC
Adding talazoparib to first-line treatment with enzalutamide can improve overall survival in patients with mCRPC, phase 3 data suggest.
The American Journal of Managed Care4d
TALAPRO-2 Overall Survival Data Suggest New Standard of Care in mCRPC, Regardless of Genomic Status
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...
Business Wire6d
Pfizer’s TALZENNA ® in Combination with XTANDI ® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, ...
The American Journal of Managed Care7d
Positive OS for Bladder Cancer Combo, Biomarkers on Tap at ASCO GU 2025
Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...
MedPage Today6d
Talazoparib-Enzalutamide Improves Survival in Metastatic CRPC
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration ...